EDN1 and coronary artery disorder: As shown in Figures 4(a)–4(c), with serum CK-MB, cTnT, and ET-1 in the CHD group significantly higher than those in control group (P < 0.001), JuA dose-dependently reduced their levels in the serum (P < 0.05).